Lynk Pharmaceuticals has concluded the dosing of the first subject in the Phase I clinical trial of its self-developed drug, LNK01004, to treat mild to moderate plaque psoriasis.

The trial in China will assess the safety, tolerability and pharmacokinetics of the LNK01004 ointment in healthy subjects, as well as mild to moderate plaque psoriasis patients.

A new kinase inhibitor, LNK01004 is intended to treat psoriasis. 

In preclinical experiments, it demonstrated good safety and efficacy. 

Furthermore, the drug is said to have the advantages of limited distribution to the skin and minimal exposure in the blood system, eliminating possible safety issues caused by its systemic exposure.

Lynk Pharmaceuticals chief development officer Dr Henry Wu said: “In preclinical translational medicine studies, we saw the favourable efficacy and safety profile demonstrated by LNK01004.

“It is a highly differentiated new molecular entity, we will continue to accelerate the clinical studies to evaluate its values as a novel therapeutic option that will benefit more patients worldwide in near future.”

A chronic inflammatory skin ailment, psoriasis is caused by a combination of genetics and environment. 

In January this year, the company dosed the first subject with its drug LNK01001 in a Phase II trial to treat ankylosing spondylitis.

This placebo-controlled, double-blind and randomised trial was designed to analyse the safety and efficacy of the capsules in patients with active ankylosing spondylitis.

Lynk focuses on discovering and developing new drugs to treat cancer, as well as immune and inflammatory ailments. 

The company has so far developed numerous drugs and initiated several clinical trials across the globe independently and with its US partner.